ATNM - Actinium Pharmaceuticals, Inc.
1.4
0.020 1.429%
Share volume: 179,151
Last Updated: 05-07-2025
Pharmaceutical Products/Pharmaceutical Preparations:
-0.13%
PREVIOUS CLOSE
CHG
CHG%
$1.38
0.02
0.01%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 04-26-2024 | 08-14-2023 | 11-02-2023 | 11-14-2024 | 04-26-2024 | 08-05-2024 | 11-14-2024 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 81.000 K | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 81.000 K | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | inf% | -100.00% | nan% | nan% | |||
| Operating expenses | 11.584 M | 15.642 M | 14.351 M | 10.424 M | 9.597 M | 12.418 M | 12.601 M | |
| Selling general and admin | 3.735 M | 4.561 M | 2.729 M | 2.306 M | 2.962 M | 3.593 M | 2.827 M | |
| Research and development | 7.849 M | 11.081 M | 11.622 M | 8.118 M | 6.635 M | 8.825 M | 9.774 M | |
| Total expenses | 11.584 M | 15.642 M | 14.351 M | 10.424 M | 9.597 M | 12.418 M | 12.601 M | |
| 35.03% | -8.25% | -27.36% | -7.93% | 29.39% | 1.47% | |||
| Operating income | -11.584 M | -15.642 M | -14.351 M | -10.343 M | -9.597 M | -12.418 M | -12.601 M | |
| Ebit | -11.584 M | -15.642 M | -14.351 M | -10.343 M | -9.597 M | -12.418 M | -12.601 M | |
| Pretax income | -11.037 M | -15.181 M | -13.276 M | -9.324 M | -8.670 M | -11.353 M | -11.568 M | |
| 37.55% | -12.55% | -29.77% | -7.01% | 30.95% | 1.89% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -11.037 M | -15.181 M | -13.276 M | -9.324 M | -8.670 M | -11.353 M | -11.568 M | |
| -37.55% | 12.55% | 29.77% | 7.01% | -30.95% | -1.89% |
